AdSS1 Inhibitors
ADSS1 inhibitors, also known as adenylosuccinate synthetase 1 inhibitors, constitute a chemical class of compounds that target a key enzyme in the purine biosynthesis pathway. This class of inhibitors primarily focuses on disrupting the activity of adenylosuccinate synthetase 1 (ADSS1), an enzyme crucial for the de novo synthesis of purine nucleotides, the building blocks of DNA and RNA. Purines play pivotal roles in various cellular processes, making ADSS1 a promising target for biochemical research and potential drug development.
ADSS1 inhibitors are designed to interfere with the enzymatic function of ADSS1 through diverse mechanisms. These compounds often mimic the structure of substrates involved in the purine biosynthesis pathway, such as adenylosuccinate or adenosine monophosphate (AMP). By binding to the active site of ADSS1, they disrupt the enzyme's ability to catalyze the formation of adenylosuccinate from inosine monophosphate (IMP) and aspartate. This disruption leads to reduced production of purine nucleotides, affecting essential cellular processes like DNA replication, RNA synthesis, and energy metabolism. Some ADSS1 inhibitors act competitively, directly competing with substrates for binding to the enzyme's active site, while others may work non-competitively, altering the enzyme's conformation or activity indirectly.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Auranofin | 34031-32-8 | sc-202476 sc-202476A sc-202476B | 25 mg 100 mg 2 g | $153.00 $214.00 $4000.00 | 39 | |
Auranofin inhibits ADSS1 by disrupting its active site, preventing the conversion of adenosine monophosphate (AMP) to adenosine diphosphate (ADP). This disruption leads to reduced nucleotide synthesis in cells, impacting their ability to proliferate. | ||||||
Mycophenolic acid | 24280-93-1 | sc-200110 sc-200110A | 100 mg 500 mg | $69.00 $266.00 | 8 | |
Mycophenolic acid is a reversible non-competitive inhibitor of ADSS1. It interferes with the enzyme's ability to catalyze the formation of AMP from inosine monophosphate (IMP), thus inhibiting purine synthesis. | ||||||
6-Mercaptopurine | 50-44-2 | sc-361087 sc-361087A | 50 mg 100 mg | $72.00 $104.00 | ||
6-Mercaptopurine acts as a competitive inhibitor of ADSS1 by resembling the structure of AMP. It competes with AMP for the active site, reducing the rate of AMP synthesis. | ||||||
Methotrexate | 59-05-2 | sc-3507 sc-3507A | 100 mg 500 mg | $94.00 $213.00 | 33 | |
Methotrexate inhibits ADSS1 indirectly by blocking dihydrofolate reductase (DHFR), which is required for purine synthesis. This leads to reduced availability of substrates for ADSS1. | ||||||
Ribavirin | 36791-04-5 | sc-203238 sc-203238A sc-203238B | 10 mg 100 mg 5 g | $63.00 $110.00 $214.00 | 1 | |
Ribavirin inhibits ADSS1 through a mechanism involving the disruption of purine biosynthesis, ultimately leading to reduced cellular proliferation. | ||||||
Leflunomide | 75706-12-6 | sc-202209 sc-202209A | 10 mg 50 mg | $20.00 $83.00 | 5 | |
Leflunomide inhibits ADSS1 by interfering with de novo pyrimidine synthesis. This indirectly affects purine synthesis by reducing the availability of pyrimidine precursors. | ||||||
Allopurinol | 315-30-0 | sc-207272 | 25 g | $131.00 | ||
Allopurinol inhibits ADSS1 by decreasing the production of xanthine and uric acid, both of which are upstream of purine synthesis. This leads to reduced AMP formation. | ||||||
Fluorouracil | 51-21-8 | sc-29060 sc-29060A | 1 g 5 g | $37.00 $152.00 | 11 | |
5-Fluorouracil is converted into active metabolites that disrupt both purine and pyrimidine synthesis pathways, ultimately inhibiting ADSS1 activity. | ||||||
2-Chloro-2′-deoxyadenosine | 4291-63-8 | sc-202399 | 10 mg | $144.00 | 1 | |
Cladribine is incorporated into DNA during replication, leading to chain termination and cell death. It indirectly affects purine synthesis, including ADSS1. | ||||||
Raltitrexed | 112887-68-0 | sc-219933 | 10 mg | $146.00 | ||
Raltitrexed inhibits thymidylate synthase (TS), which is essential for DNA synthesis. This indirectly impacts ADSS1 by reducing the availability of deoxyadenosine monophosphate (dAMP). | ||||||